Canaan adds $100M+ to boost biopharma investing, brings on former Pfizer exec

Canaan, a decades-old tech and life sciences venture capital firm, plans to invest more heavily in biopharma going forward.

The Menlo Park, CA-based firm added more than $100 million to its 13th fund and brought former Pfizer executive Uwe Schoenbeck on board as a venture partner, it said Wednesday morning. Schoenbeck has already helped Canaan scout investments and led the firm to contribute to the $132 million Series B for cancer biotech Alterome earlier this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot.

December 14, 2023

PEPFAR has been a lifeline in Ukraine. Now it’s under threat

In Ukraine, a little bit of good news can go a long way, and the lifesaving work being done as a result of the President’s Emergency

December 1, 2023

Optibrium’s Quantum Mechanics and Machine Learning Methods Predict Routes of Drug Metabolism

Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity

December 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.